Novo Nordisk Pharmatech showing enhanced recombinant insulin advantages at Biologics Manufacturing Korea

Novo Nordisk Pharmatech showing enhanced recombinant insulin advantages at Biologics Manufacturing Korea

NovoNordics 150x58

News | Novo Nordisk Pharmatech A/S

MAY 14, 2018

Køge, Denmark: – Leading supplier of recombinant human insulin, Novo Nordisk Pharmatech, will use one of Asia’s leading biotech events, Biologics Manufacturing Korea 2018 in Seoul, to show how recombinant adding insulin to the cell lines can have a positive effect on the cell culture.

The innovative Danish supplier, which is the world’s leading suppliers of recombinant insulin in cell culture media, powering biopharma blockbuster drugs worldwide, will exhibit its capabilities from Booth 11 in the exhibition zone at the Novotel Ambassador Gangnam in the South Korean capital.

They will be showcasing the company’s recombinant insulin as a key component in growth media for mammalian cells with significant advantages in bioprocess optimization, high cell viability and higher productivity in the upstream manufacturing process.

Once again, visitors to the Novo Nordisk Pharmatech stand will have the chance to win an Amazon Kindle.

Manufacturing of innovative biologics

Marketing Manager Vanessa Leon and Sales Manager Magnus Franzmann and will lead the Novo Nordisk Pharmatech presence at the event.

“Our new recombinant insulin is highly relevant for the topics being discussed at this meeting,” commented Magnus Franzmann.

“It can be used in cGMP manufacture of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA,” said Mr. Franzmann.

Increased cell density

“This event gives us a great opportunity to reach out to Korean, Japanese and Taiwanese-based biopharmaceutical companies working in cell line development. Our recombinant insulin can help them enhance their cell line media growth with optimized cell density and viability,” he added.

The team will be able to show how Novo Nordisk Pharmatech technology can Increase viable CHO cell density in commercial available cell culture media by supplementation with non-animal insulin. Research in collaboration with UAB has demonstrated that adding animal origin free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density as well as aiding expression of difficult proteins.

About Novo Nordisk Pharmatech

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totalling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About Biologics Manufacturing Korea

Biologics Manufacturing Korea (also known as Biologics World Korea) bills itself as the only biologics and biosimilars-focused event in the Republic of Korea.

The 7th Biologics World Korea is a three-day event, opening May 29, once again at the Novotel Ambassador Gangnam Hotel in Seoul.

The annual event was founded in 2012, with a mission to facilitate development and manufacturing of high quality biologic drugs and vaccines in Korea for the world market. Since then it has grown to encompass more than 550 biologics industry companies from Korea and overseas.

For 2018, Biologics Manufacturing Korea will feature ten tracks, including sessions on reducing timelines with more efficient screening technologies and monitoring bioprocesses, incorporating QbD in early process development, single-use biomanufacturing facilities and optimization of downstream purification for highly complex molecules.

The event is organized by IMAPAC, with more information at:

Media Contact

Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84


Click on Novo Nordisk Pharmatech at Biologics Manufacturing Korea 2018 for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
Click on Increasing viable CHO cell density in commercial cell culture media to learn more about Novo Nordisk Pharmatech’s offer.

Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebenhavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483

Comments are closed.